seed
Stage
1
Investors
About
Ermium Therapeutics was a biotechnology company developing functionally selective immunomodulators targeting the CXCR4 receptor for autoimmune diseases, particularly interferonopathies such as systemic lupus erythematosus (SLE). The company ceased operations in 2024.
Explore Ermium Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.